Abstract: Poster Presentations |


James M. Stocks, MD*; Mark Brantly, MD; Alan Barker, MD; Friedrich Kueppers, MD; Charlie Strange, MD; James F. Donohue, MD; Robert Sandhaus, MD
Author and Funding Information

University of Texas Health Center at Tyler, Tyler, TX


Chest. 2005;128(4_MeetingAbstracts):261S. doi:10.1378/chest.128.4_MeetingAbstracts.261S-b
Text Size: A A A
Published online


PURPOSE:  This study evaluated the bioavailability of a new preparation of alpha1-proteinase inhibitor (A1-PI), Zemaira® (ZLB Behring LLC, [Z(A1-PI)]), with that of Prolastin® (Bayer Corporation, [P(A1-PI)]) after single intravenous infusions.

METHODS:  This was a double-blind, randomized, controlled, 2x2 crossover study comparing a single dose of Z(A1-PI) and P(A1-PI) (60 mg per kg bodyweight). Patients with AATD were randomized (n=9 per group) to Z(A1-PI) followed by P(A1-PI), or P(A1-PI) followed by Z(A1-PI), with a washout period between infusions of 35 days. Bioavailability was measured by two baseline-adjusted area-under-the-curve (AUC) variables: area-under-the observed data up to Day 21 (AUD0-21) and AUD0-∞. The ratio of mean AUC variables (Z(A1-PI):P(A1-PI)) with 90% confidence intervals (CI) was calculated. Standard pharmacokinetic (PK) parameters Cmax, tmax, terminal t 12 , mean residence time, total clearance, and steady-state volume of distribution were also compared.

RESULTS:  The bioavailability of Z(A1-PI) was statistically non-inferior to P(A1-PI) as shown by the lower limit of the 90% CI for the mean AUC ratio (Z(A1-PI):P(A1-PI)) being greater than 80% for AUD0-21 and also for AUD0-∞ (Table). Furthermore, the PK profile of functional A1-PI levels following Z(A1-PI) and P(A1-PI) administration showed no clinically relevant differences in terms of mean (SD) Cmax (39.9±5.3 vs. 41.6±8.0 μM), tmax (0.7±0.3 vs. 1.5±1.4 hours), terminal t 12  (4.5±3.1 vs. 4.8±1.2 days), mean residence time (5.9±3.3 vs. 6.1±1.3 days), total clearance (636±115 vs. 583±108 mL/day) or steady-state volume of distribution (3.6±1.3 vs. 3.5±0.8 L). The PK profile was reflected by that of antigenic A1-PI levels.

CONCLUSION:  A single therapeutic dose of Z(A1-PI) was comparable and statistically not inferior to P(A1-PI) in bioavailability. There were no differences between Z(A1-PI) and P(A1-PI) in standard pharmacokinetic parameters.

CLINICAL IMPLICATIONS:  Since Z(A1-PI) is statistically not inferior to P(A1-PI) in bioavailability, a weekly infusion of Z(A1-PI) 60 mg per kg body weight is expected to augment and maintain A1-PI serum levels above the protective threshold of 11 μM, and increase A1-PI levels in the lower lung, to a similar extent to that reported with P(A1-PI).

DISCLOSURE:  James Stocks, None.

Wednesday, November 2, 2005

12:30 PM - 2:00 PM




Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543